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Abstract The induced pluripotent state represents a
decade-old Nobel prize-winning discovery. Human-
induced pluripotent stem cells (hiPSCs) are generated by
the nuclear reprogramming of any somatic cell using a
variety of established but evolvingmethods. This approach
offers medical science unparalleled experimental opportu-
nity to model an individual patient’s disease Bin a dish.^
HiPSCs permit developmentally rationalized directed dif-
ferentiation into any cell type, which express donor cell
mutation(s) at pathophysiological levels and thus hold
considerable potential for disease modeling, drug discov-
ery, and potentially cell-based therapies. This review will
focus on the translational potential of hiPSCs in clinical
neurology and the importance of integrating this approach
with complementary model systems to increase the trans-
lational yield of preclinical testing for the benefit of pa-
tients. This strategy is particularly important given the
expected increase in prevalence of neurodegenerative dis-
ease, which poses a major burden to global health over the
coming decades.
Keywords Cellular therapy . Disease modeling . Drug
discovery . Human induced pluripotent stem cells
(hiPSCs) . Neurology . Translational medicine
Introduction
Medicine has evolved a sophisticated taxonomic reper-
toire that is based upon particular constellations of pre-
dominantly clinical and macroscopic/imaging features.
Although such an approach has clear utility in medical
practice, it leaves unresolved to some extent the cellular
and molecular basis of disease. It follows that a com-
plementary taxonomic (re)classification to reflect under-
lying—and potentially therapeutically targetable—mo-
lecular mechanisms may serve to strengthen both our
diagnostic and therapeutic capacities. In order to first
gain accurate insight into the molecular basis of human
disease, it is crucial to employ an integrated approach
that recognizes inherent limitations in each model sys-
tem when used in isolation. Animal models and human
non-neuronal cell lines have provided invaluable insight
into developmental and translational neuroscience. Yet
their success in identifying novel and clinically impact-
ful therapies has been underwhelming, perhaps
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reflecting an inability to capture the true complexity of
human neurological disease by using these approaches
in isolation. Advances over the last decade have trans-
formed the landscape of mechanistic evaluation and
drug discovery in neurodegenerative disease, with new
technologies permitting the study of previously inacces-
sible human cellular subtypes. The induced pluripotent
state represents a Nobel prize-winning discovery made
in the laboratory of Shinya Yamanaka in Kyoto, Japan,
in 2006 and 2007 (Takahashi and Yamanaka 2006;
Takahashi et al. 2007). Human-induced pluripotent stem
cells (hiPSCs) are generated by the nuclear
reprogramming of any somatic cell using either genome
integrating or non-integrating Bfootprint-free^ methods
(reviewed in Gonzalez et al. 2011). This approach offers
medical science considerable and unprecedented exper-
imental opportunities to model an individual patient’s
disease Bin a dish.^ HiPSCs permit ontogeny-
recapitulating directed differentiation into any human
cell types, which themselves express donor cell muta-
tion(s) at pathophysiological levels and thus hold con-
siderable potential for disease modeling, drug discovery
and potentially cell-based therapies.
Modeling neurodegeneration: the role of hiPSCs
The failure in clinical translation from preclinical
models is particularly evident in the field of neurode-
generative disease, possibly arguing for the requirement
of a human experimental system to complement—but
not replace—existing models. While human postmor-
tem tissue provides a valuable resource for investigating
the end-stage pathological processes in a clinical dis-
ease, it does not allow dynamic insight into initiating
molecular pathogenic events. HiPSCs possess two de-
fining attributes: (i) the ability to self renew and (ii) the
capacity to differentiate into any of the cell types com-
prising the organism from which they are derived.
However, with this potential comes the complexity of
directing differentiation into highly refined and region-
ally specified subtypes of neurons and glia (see Fig. 1).
This paradigm utilizes insights from developmental
biology to rationalize a program of stage-specific mor-
phogenetic instructions in order to predictably manipu-
late cell fate to desired lineages. These attributes—when
considered with the fact that one can generate patient-
specific hiPSCs—justify current enthusiasm about this
technology to help elucidate cellular and molecular
determinants of human disease. One major utility of this
model is to resolve the functional cellular and molecular
sequelae of monogenetic diseases, an approach that has
now been validated by myriad studies including adult-
onset conditions. Indeed, well-characterized and devel-
opmentally rationalized protocols for neuronal and glial
specification (reviewed elsewhere; Zirra et al. 2016;
Goldman and Kuypers 2015; Tyzack et al. 2016;
Patani 2016) have been employed on a range of
patient-derived hiPSCs for both monogenic and sporad-
ic neurodegenerative diseases to define disease-related
phenotypes (see Table 1 for representative examples).
The differentiation of clearly defined and functional
cellular subtypes from stem cells provides the opportu-
nity not only to elucidate but also to put into precise
sequence the molecular steps culminating in cellular
demise by conducting time-resolved experiments.
However, in patients, these cells do not exist in isolation
and, therefore, developing incrementally complex neu-
ronal circuits, neuron-glia co-culture paradigms, and
complex 3D Borganoids^ are likely to deepen our un-
derstanding of these diseases (reviewed in Clevers
2016). RNA sequencing has been used to identify po-
tential pathological pathways in an unbiased manner
and, coupled with gene editing to correct a mutation,
provide evidence that phenotypes detected are mutation-
dependent (Kiskinis et al. 2014; Reinhardt et al. 2013).
Indeed, an experimental workflow for such an approach
has recently been proposed (Merkle and Eggan 2013).
Identification of early pathological processes—includ-
ing post-transcriptional mechanisms of disease (Patani
et al. 2012b)—offers the prospect therapeutic target
definition for intervention at a presymptomatic/early
symptomatic stage.
Maturational status of terminally differentiated
neurons and glia
We and others have studied the maturity of terminally
differentiated pluripotent stem cell-derived region-spe-
cific neurons using genome-wide gene expression and
splicing analysis and found that they represent a fetal
developmental state when compared to isotopic but
anisochronic somatic counterparts (Patani et al. 2012a;
Miller et al. 2013; Ho et al. 2016). This finding may
bring into question their ability to model adult onset
conditions. Yet, patient-specific hiPSCs have now been
robustly shown across a range of neurogenetic
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conditions—summarized in Table 1—to possess the
capacity to capture early pathogenic events in a
mutation- and cell type-dependent manner. The ability
to model adult-onset conditions in what is essentially a
developmental system can be reconciled by the possi-
bility that the in vivo environment (glial-neuronal
interaction for example) may help to compensate cell
autonomous neuronal dysfunction. Recognizing the
ability of hiPSC derivatives to capture disease-relevant
phenotypes then raises the interesting issue of how early
the presymptomatic phase may actually begin (i.e., the
duration of Bcompensated neuronal dysfunction^).
Indeed, important insights have been gained by studying
even neural precursors in certain familial forms of
schizophrenia (Yoon et al. 2014), familial dysautonomia
(Lee et al. 2012; Lee et al. 2009), and hereditary spastic
paraparesis (Mishra et al. 2016), reinforcing the utility of
this approach for elucidation of developmental pheno-
types in pre-manifest disease states. In other cases,
differentiated cell types have been exposed to stressors
in order to elicit a phenotype (Reinhardt et al. 2013;
Nguyen et al. 2011; Donnelly et al. 2013).
Can we do anything to accelerate aging of hiPSC-
derived neurons so they more faithfully represent their
adult counterparts? Epigenomic changes including
those in transcriptional and chromatin networks are
observed with aging (Booth and Brunet 2016).
Therefore, to comprehensively study neurodegenerative
disease, it may be a complementary strategy to induce
aging in hiPSC models as a useful comparator. To this
end, experiments from Lorenz Studer’s group have
demonstrated that progerin-induced aging of hiPSC-
derived midbrain dopaminergic neurons to a more
adult-like state is achievable (Miller et al. 2013). A more
recent study from Fred Gage’s laboratory systematically
compared hiPSC-derived neurons with direct conver-
sion/‘transdifferentiation’ from patients across a diverse
age range to confirm that reprogramming Bresets^ age,
while transdifferentiation preserves donor age, thus
highlighting the complementarity of these paradigms
to study age-dependent phenotypes (Mertens et al.
2015). Indeed, direct conversion to multiple region-
specific and clinically relevant neuronal and glial sub-
types has also been achieved (Son et al. 2011; Caiazzo
et al. 2011; Yang et al. 2013a; Caiazzo et al. 2015),
reinforcing the practical feasibility of comparative stud-
ies between direct conversion and hiPSC directed dif-
ferentiation paradigms. A further interesting approach to
inducing/accelerating aging of hiPSC-derived sympa-
thetic neurons was their functional connection with
Fig. 1 A schema depicting the generation of human-induced
pluripotent stem cells from patient fibroblasts followed by sequen-
tial phases of lineage restriction. Directed differentiation para-
digms can generate region-specific neural precursors, which can
subsequently be differentiated into neurons, astrocytes, and oligo-
dendrocytes. Diagrams were drawn using templates freely avail-
able from Servier Medical Art (http://www.servier.co.
uk/content/servier-medical-art)
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cardiomyocytes (Oh et al. 2016). This study harnessed
developmentally rationalized directed differentiation
and in vivo circuitry to foster maturation status.
Genomic variation between hiPSC lines
Line-to-line variability continues to be a concern among
stem cell biologists. However, significant advances in
gene editing through zinc finger nucleases (ZFNs,Wood
et al. 2011), transcriptional activator-like effector nucle-
ases (TALENs, Boch et al. 2009), and more recently the
development of the clustered regularly interspaced short
palindromic repeats (CRISPR)-associated system
(CRISPR/Cas9, Cong et al. 2013) allow the generation
of isogenic controls to increase confidence in identify-
ing mutation-dependent cellular and molecular pheno-
types. These approaches and their practical utility in
patient-specific hiPSCs have been recently reviewed
elsewhere (Hendriks et al. 2016). Genome editing tech-
nologies are particularly relevant to monogenic diseases
rather than complex genetic disorders or sporadic dis-
ease (Shribman et al. 2013; Samani et al. 2015; Patani
et al. 2013; Athappily et al. 2013). An ideal approach for
mendelian disorders is to generate reciprocal isogenic
lines for a given mutation being studied—i.e., the mu-
tation is corrected to create one isogenic pair, and it is
separately inserted into a control line to generate a
second isogenic pair (Liu et al. 2012). An alternative
approach to genome editing is to utilize larger numbers
of control and mutant lines, but this has the potential to
become prohibitively time- and resource-consuming,
although feasibility has already been demonstrated in
the context of a large and cohesive consortium
(Consortium 2012).
Generating isogenic controls, standardizing optimal
differentiation protocols, and reproducing mutation-
dependent phenotypes across different laboratories are
important considerations in future work. Additionally,
intensive characterization of several lines derived from
ethnically diverse control cases also has value to serve
as a reference point, particularly if these lines are made
available to other investigators. Such an approachwould
not only provide an invaluable resource but would also
significantly reduce costs for stem cell researchers.
Indeed, the hiPSC field has begun to achieve such stem
cell repositories and had the foresight to include
Bsecondary products^ (e.g., reporter lines). This strategy
promotes data sharing and comparison. Further
attributes including integration-free lines, equal male
and female line representation, and the prospect of in-
tensively characterized cryopreservable differentiated
precursors make such stem cell repositories an attractive
prospect. Such non-profit initiatives also stand to benefit
from close collaboration with industry.
Compound screening and drug discovery
Drug development is expensive and time-consuming,
and those therapeutics that do emerge from preclinical
studies have a low conversion rate into successful dis-
ease treatments due to limitations with either safety or
efficacy. This failure of translation is particularly evident
in the field of neurodegeneration, where only a very
small percentage of drugs that reach the development
phase are actually ever marketed (Ringel et al. 2013;
Rubin 2008). Some putative reasons for this failure
include (i) selection of diseases where the molecular
pathogenesis is poorly understood, this precluding a
mechanistically rationalized approach (ii) over reliance
on onemodel system or the use of models that have poor
predictive value of clinical success (e.g., due to
interspecies differences, Peng et al. 2013; Seok et al.
2013; Scannell et al. 2012), (iii) candidate compounds
that have poor safety profiles or (iv) pharmacodynamic
properties (e.g., do not penetrate the blood-brain barri-
er), and (v) clinical trial design that is suboptimal due to
patient heterogeneity and/or lack of appropriate end
point measures.
The historical inaccessibility to most adult hu-
man neural cell types has consequently prevented their
experimental integration into preclinical testing. In the
last decade since their discovery, hiPSC models have
already successfully identified promising compounds
preclinically, some of which have since entered clinical
trials (Wainger et al. 2014; Kiskinis et al. 2014). It is also
noteworthy that drugs, which previously failed in ex-
pensive clinical trials, have also been shown to fail in
relevant hiPSCmodels (Yang et al. 2013b), highlighting
their utility/predictive power in preclinical testing. High
throughput assays of patient-derived neurons and glia
therefore offer the potential to transform preclinical
testing when integrated with current in vivo approaches
(see Fig. 2). Furthermore, due to one of their defining
attributes of potentially limitless self-renewal, there is a
theoretically unlimited supply of cellular material.
Indeed, 3D culture techniques have been shown to allow
Cell Biol Toxicol (2017) 33:129–144 133
the maturation of billions of uniform cells in a single
flask (Rigamonti et al. 2016). Such scalability will in
turn allow more comprehensive optimization of dosing
regimen as well as concentration and duration of treat-
ment through systematic fine-tuning, rather than the
somewhat arbitrary dosing regimen currently in place
for many drugs used in clinical medicine.
Characterizing a population of cryopreservable
intermediate neural derivatives (e.g., region-specific
precursors) would further improve scalability of cul-
tures for high-content cell-based screening ap-
proaches. High-throughput screening has been used
to identify compounds that can optimize directed
differentiation of hiPSCs (Han et al. 2009; Maury
et al. 2015) and demonstrates practical feasibility of
employing such approaches for drug discovery.
Indeed, this method has revealed important cell
type- and species-specific effects, both in terms of
toxicity and neuroprotective effects (Peng et al.
2013). A recent study performed a large-scale com-
pound screen with hiPSC-derived neural precursor
cells to decrease the Zika virus infection, demon-
strating the utility of high-throughput approaches at
the neural precursor stage (Xu et al. 2016). Some
further representative examples of studies that have
exploited hiPSC-derived neural precursors and/or
neurons for drug discovery and toxicity assessment
are provided in Table 2 below. The repertoire of live
content readouts is steadily increasing; robust and
commercially available assays include live/dead,
neurite length/complexity, and mitochondrial integ-
rity, to mention a few. The prospect of multiplexing
these parameters in a human neuronal system is
attractive from a disease modeling perspective.
Some drug discovery efforts have focused on
Brepurposing^ FDA-approved drugs. This approach al-
lows significant reduction of time to clinical use.
Conversely, a 5–8-year period is required from identify-
ing a hit using conventional compound library screening
due to further necessary medicinal chemistry/drug opti-
mization. It is likely that in many diseases, particularly
degenerative processes, combinations of drugs may
prove necessary for optimal therapeutic effect. From
this perspective, the field of neurodegeneration can
glean some relevant insights into therapeutic strategy
from cancer biology. Furthermore, different drugs might
Fig. 2 Aworkflow for using human-induced pluripotent stem cell
derivatives for disease modeling, drug discovery, and toxicity
assays in high throughput. Diagrams were drawn using templates
freely available from Servier Medical Art (http://www.servier.co.
uk/content/servier-medical-art)
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be required either sequentially and/or combinatorially at
distinct pathological Bphases^ within the context of a
disease (e.g., relapsing-remitting vs. secondary progres-
sive multiple sclerosis). Within defined phenotypes at a
particular disease phase, it is important to experimental-
ly resolve the crucial pathogenic event(s) in order to
guide therapy development around such validated tar-
gets specifically.
The approach of screening compound libraries is
important to inform which mechanistic phenomena
are therapeutically manipulable. Important issues to
address in the future (over and beyond the afore-
mentioned stage-specific and combinatorial thera-
pies) include screening compounds on enriched pop-
ulations of specific cell types in mono- and co-
culture. Furthermore, systematic approaches to opti-
mizing the duration of therapy, drug concentration,
and timing of initiation relative to disease phase are
all important considerations. Integrated medicinal
chemistry expertise is then crucial to optimize the
compound for clinical trial use. To this end, it is
essential to ensure that any potential compound is
safe in humans, which highlights another role for
hiPSC derivatives as a predictive cell-based model
for toxicity assessment. HiPSCs themselves do not
faithfully capture the physiological attributes of clin-
ically relevant somatic cell types (e.g., those of the
liver, kidney, heart, and brain) and thus cannot serve
as appropriate model for predictive toxicity assess-
ment. However, using ontogeny-recapitulating di-
rected differentiation of hiPSCs to desired cell types
allows more accurate toxicity assessment in a rele-
vant cellular context (see Fig. 2). Drug development
attrition rates are high as current assays do not
always reflect damage to hepatic, renal, cardiac,
and neuronal cells at least partially due to species
differences in metabolism. Hepatocytes from donor
tissue have been used to model drug toxicity; how-
ever, they are limited by scarcity of donor tissue,
and high-quality tissue which is available is used—
quite rightly—for donation (Greenhough et al.
2010). Hepatocyte-like cells have been differentiated
from hiPSCs with success by several groups (Siller
et al. 2015). A generic hepatocyte library to test
therapeutic drugs in high-throughput screening for
liver toxicity would be an invaluable resource, along
with similar approaches for other aforementioned
organ systems. Optimized rapid differentiation pro-
tocols in the future may offer the opportunity for
personalized toxicity screening, which in turn would
permit the formulation of a bespoke therapeutic
strategy accounting for a patient’s own genetic
polymorphisms.
Cellular therapy
Strategies for generating patient-specific neuronal and
glial subtypes—through either reprogramming and di-
rected differentiation or direct conversion methods—
have fuelled excitement about the prospect of cellular
therapy to restore structure and function in neurodegen-
erative diseases. Issues of safety are paramount in this
context and broadly include rigorous tumorogenicity
and immunogenicity testing, recently reviewed else-
where (Xie and Tang 2016; Neofytou et al. 2015).
Additionally practical feasibility includes assuring au-
thenticity of cell fate, scalability, and enrichment (e.g.,
generating a billion cells >95% enriched for a particular
neuronal subtype would be an approximate manufactur-
ing benchmark). There are broadly two cellular sources
that one can consider—autologous (theoretically remov-
ing the need for immunosuppression) or allogeneic/
BHLA matched.^ It is also important to consider the
goal of therapy at the cellular/molecular level—restora-
tion of structure and function will require ontogeny-
recapitulating differentiation of the cellular graft (e.g.,
authentic midbrain dopaminergic neurons in the case of
Parkinson’s disease). Conversely, implanted cells may
invoke/strengthen endogenous mechanisms of repair
through local effects on neighboring cells. Geron
Corporation initiated the first human stem cell trial for
spinal cord injuries in 2010, but unfortunately this was
discontinued shortly afterwards for business-related
strategic (rather than scientific) reasons (Scott and
Magnus 2014; Lebkowski 2011). In order to illustrate
the relevant principles of cellular therapy here, we have
considered two examples in some detail; Parkinson’s
disease and age-related macular degeneration.
Additional examples of relevant studies utilizing human
iPSC-based cellular therapies for neurological disorders
are then summarized in Table 3.
There is a significant history to cellular therapy in
Parkinson’s disease, particularly in the 1-methyl-4-phe-
nyl-1,2,3,6-tetrahydropyridine (MPTP) primate model,
which exhibits a characteristic loss of midbrain dopami-
nergic neurons in the substantia nigra and phenocopies
the human condition. Transplantation of human fetal
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neural stem cells into this model was found to amelio-
rate the disease phenotype. Noting that there is a proven
relationship between graft survival and amelioration of
the disease course (reversal of motor deficits), the find-
ings within the same study of only a small minority of
graft TH+ve donor cell survival required further expla-
nation. Indeed, >95% remained as neural precursors and
hence the mechanism of functional improvement was
likely not to be exogenous cellular replacement, but
rather influences of the graft on endogenous cellular
function (Redmond et al. 2007; Bjugstad et al. 2008).
For reasons alluded to earlier, human pluripotent—in-
cluding induced and embryonic—stem cells (hiPSCs/
hESCs) have several attractive features in this context
including self-renewal and capacity for predictable ma-
nipulation using extrinsic developmentally rationalized
cues. However, when hESC-derived midbrain dopami-
nergic neurons are implanted into a primate model of
PD, disappointingly no TH+ve cells were again found to
survive at postmortem analysis (Wakeman et al. 2014).
Against this background, the authenticity of midbrain
dopaminergic specification was re-evaluated. Indeed, it
was previously demonstrated through a series of elegant
experiments that FOXA2 is a key transcription factor for
the specification of authentic midbrain dopaminergic
neurons (Kittappa et al. 2007). The Studer lab next
conducted groundbreaking work that built on this dis-
covery, where authentic midbrain dopaminergic neurons
(generated by first specifying floorplate cells rather than
progression through a neural rosette paradigm) were
transplanted into rodent and primate models of
Parkinson’s disease. Crucially, these interventions
yielded both functional amelioration and survival of
TH+ve/FOXA2+ve neurons 3 months post-transplant
(Kriks et al. 2011). This represented a milestone
achievement in this field. Subsequent work has consid-
ered implanting patient-specific hiPSC (rather than
hESC)-derived midbrain dopaminergic (mDA) neurons.
This was first tested in an MPTP primate model. Three
months post-transplant, the mDA neurons mature in the
host brain, retaining their BA9^ molecular phenotype. It
remains unresolved as to which source of dopaminergic
neurons is optimal for transplantation into Parkinson’s
disease patients, and the field stands to benefit from
direct comparison of fetal, hESC-, and hiPSC-derived
cellular grafts in the context of longitudinal clinical and
pathological follow-up studies (Brundin et al. 2010).
Excitingly, the first hiPSC trial into human patients
with age-related macular degeneration took place in
2014 where autologous hiPSC-derived retinal pigment
epithelial cells were implanted (Chakradhar 2016). The
intervention seemingly ameliorated progression in the
first patient 1 year post-transplant, and no adverse ef-
fects were reported. However, quality checking of a
second hiPSC line revealed mutations that were not seen
in the somatic cells from which they were derived,
consistent with previous reports (Gore et al. 2011). At
this stage, the trial was suspended given unknown on-
cogenicity of the cell lines and costs of generating an
autologous hiPSC line for each patient treated. The
laboratory leading this work has confirmed that they
will now turn their attention towards allogeneic
hiPSCs (Garber 2015), which may indeed prove to be
more cost-effective given that a total of approximately
150 preselected donors, (constituting a Bhaplobank^)
could cater for the vast majority of the population in
the UK (Taylor et al. 2012). The infrastructure here
could follow basic design principles of blood banks,
although an hiPSC haplobank would clearly require
bespoke processes and quality control. It also presup-
poses equal potency between hiPSC lines, which is not
always practically achieved (Hu et al. 2010; Boulting
et al. 2011). Although the nervous system is an immu-
nologically Bprivileged^ site, the precise requirement
for immunosuppression in neural grafting remains un-
resolved. There is therefore a balance to be struck be-
tween utilizing comprehensively characterized alloge-
neic lines versus Bpersonalized^ autologous hiPSCs; the
former seems to be a more practically and financially
viable option in the immediate future. Further caution is
required when one considers the potential toxicity of
hiPSC-based cellular therapy specifically in the context
of tumor formation. Reprogramming of somatic cells
often utilizes lentiviral or retroviral strategies, raising the
issue of random integration within the human genome
of the host and related oncological consequences (Howe
et al. 2008; Okita et al. 2007). Indeed, the process of
directed differentiation itself may trigger a resurgence of
exogenous transgene transcription (Okita et al. 2007).
Some of this risk can be mitigated by using non-
integrating (and even non-viral) approaches to
reprogramming. It is also possible that upon transplan-
tation into a diseased environment, the hiPSC deriva-
tives may be vulnerable to the disease for which they are
being implanted. Such spread of disease into stem cell
grafts has already been demonstrated in the context of
fetal ventral mesencephalic transplantation in
Parkinson’s disease (Li et al. 2008). Indeed, similar
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concerns may exist with autologous transplantation of
hiPSC derivatives, especially in genetic diseases. Recent
advances in genome editing can at least partially temper
this concern, where a specific mutation can be
Bcorrected^ in patient-specific iPSCs prior to autologous
transplantation. Several varieties of customized nucleases
are now established for genome editing, including zinc
finger nucleases (ZFNs), transcription activator effector
nucleases (TALENs), and the CRISPR-Cas9 system
(Urnov et al. 2010; Sander and Joung 2014; Joung and
Sander 2013). Significant optimization in both the design
and quality checking of these approaches provides some
early promise for their practical utility in regenerative
medicine (Tsai and Joung 2014).
Current evidence suggests that cellular therapies can
restore structure and function to some degree, but in order
to be clinically tractable, they must first be shown to be
superior to the current standard of care. Given that no
disease-modifying therapies currently exist for most neu-
rodegenerative diseases, it is the hope that cellular strate-
gies may slow down, halt, or ideally reverse disease
progression. An interesting idea to consider here is com-
binatorial therapy (e.g., cellular transplant plus GDNF
infusion in the case of Parkinson’s disease), which may
be required to achieve clinically evident disease modifi-
cation. Crucially, clinical trials need careful design includ-
ing predefined end points, rigorous safety assessment,
reproducible cellular derivation, tumorogenicity assays,
and demonstration of preserved efficacy in the context
of immunosuppression. To realize cellular therapies for
neurodegenerative disease, it is clear that transparent in-
ternational collaboration will be a key driving force.
Concluding remarks
HiPSCs hold tremendous promise for translational re-
search in neurological disease (Connick et al. 2011).
Although considerable advances have been made to
date, these have not yet been optimally translated direct-
ly into improved patient care, which is the ultimate goal.
Continuing advances in the directed differentiation of
patient-specific hiPSCs into highly enriched populations
of neuronal and glial subtypes will undoubtedly im-
prove the precision of modeling cell type-specific phe-
notypes. There are certain regions of the neuraxis that
have proved difficult to derive in vitro from hiPSCs such
as the cerebellum (Wiethoff et al. 2015), although there
have been recent promising advances (Wang et al.
2015). One important future goal is to conduct stage-
defined transcriptome-wide analyses throughout human
brain development from pluripotency through to adult
old age and to include different neuraxial regions as they
emerge and mature. This transcriptional atlas will, dur-
ing its evolution, inform and guide directed differentia-
tion strategies to multiple less well-studied neuraxial
regions. Cell-based high-throughput screening methods
for both ameliorating disease-specific phenotypes and
toxicity assays will converge to reinforce a personalized
approach to patient management. An important aspect to
invest in for future studies is establishing salient (i.e.,
disease causing) phenotypes, which will necessitate dis-
crimination of primary from secondary pathogenic
events in time-resolved analyses. Functional genomic
technologies with bespoke bioinformatics pipelines
have proved powerful as unbiased approaches in
Fig. 3 An organogram providing
a framework within which
human-induced pluripotent stem
cells can be harnessed in the
emerging discipline of
regenerative neurology. Diagrams
were drawn using templates
freely available from Servier
Medical Art (http://www.servier.
co.uk/content/servier-medical-art)
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elucidating transcriptional phenotypes, which can then
be followed up in a hypothesis-driven manner. These
advances coupled together with robust genome editing
technologies are converging to help realize the promise
of hiPSCs in regenerative neurology (see Fig. 3).
In future, we envisage diagnostic and therapeutic
integration of patient-specific hiPSCs into clinical man-
agement. As a first step, this might involve rapid
reprogramming and differentiation of patient-specific
cells followed by a personalized regimen of drugs se-
lected through high-throughput screening with concur-
rent toxicity assays. How soon this future can become a
reality depends not only on scientific advances but also
on practical and financial feasibility. The prospect of
automating the majority of hiPSC culture is crucial to
ensure scalability and reproducibility across experi-
ments. This would also reduce cell culture demands on
researchers and the risk of infection. Such technologies
are now available, although wider usage is likely limited
by cost. Clinically impactful advances in the hiPSC field
will undoubtedly be realized sooner through cohesive
international consortia and the closer collaboration/co-
location of industry with both academic and clinical
colleagues, in order to drive drug discovery and trans-
lational neuroscience towards an era of precision
medicine.
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